Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

早期前列腺特异性抗原（PSA）下降及其速度是接受醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌（mCRPC）患者预后的独立预测因素。